STAT August 8, 2024
Morning! Today, a handful of STAT reporters pore through former President Trump’s own remarks over the past year or so to get a sense of his health care agenda. Also, we learn the new priority in CRISPR therapies is delivery, and more.
The need-to-know this morning
- Eli Lilly boosted 2024 revenue guidance by $3 billion on strong Mounjaro, Zepbound sales.
- Apellis Pharmaceuticals announced positive results from a Phase 3 study of its approved drug Empaveli in patients with two types of rare kidney disease. The company plans to seek FDA approval in early 2025. Its marketing partner Sobi will also apply for European approval next year.
- Merck halted a Phase 3 clinical trial of its anti-TIGIT drug vibostolimab in...
Today's Sponsors
Today's Sponsor